 MELBOURNE, Australia, Jan. 11, 2021 GLOBE NEWSWIRE -- Immuron Limited ASX: IMC; NASDAQ: IMRN, an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut pathogens, today is pleased to announce that Chief Executive Officer, Dr Jerry Kanellos, will participate in the H.C. Wainwright Co. BioConnect 2021 Virtual Conference in January 2021 during J.P. Morgan week. 